Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Sizing up tumours with Tuba-seq

Credit: Sergio Amiti/Moment/Getty

Precise determination of tumour growth is a prerequisite for estimating the functional importance of tumour suppressor alterations in cancer. A study in Nature Methods now describes the development of Tuba-seq, an approach that integrates tumour barcoding with high-throughput sequencing, to precisely quantify the size of individual tumours in vivo.

“read counts of barcodes were converted to estimated cell numbers”

The new method relies on the use of lentiviral Cre-vector libraries that contain DNA barcodes to stably tag individual lesions with a unique identifier. In a genetically engineered mouse model of human lung cancer, transduction of lung epithelial cells leads to Cre recombinase-mediated expression of oncogenic Kras. Expression of this oncogene induces the simultaneous development of multiple tumours, each now tagged with a unique 15-nucleotide (nt) barcode. In a first set of experiments, the Kras-driven tumours were analysed side-by-side with lung tumours that carried additional deficiencies in the tumour suppressor genes Lkb1 or p53. High-throughput sequencing was performed on bulk tumour DNA, and read counts from barcodes were converted to estimated cell numbers based on mixed-in 'benchmark' cells. Tuba-seq accurately determined the number of neoplastic cells in all tumours in parallel, finding them to be more than 1,000-fold different in cell number. The size distribution of tumours further provided insight into the different mechanisms of action of p53 and LKB1 (also known as STK11) in suppressing tumour growth.

Having demonstrated the utility of Tuba-seq, Rogers, McFarland, Winters et al. set out to adapt the method for multiplexing, this time using CRISPR–Cas9-mediated inactivation of 11 known or suspected tumour suppressors in the Kras-driven lung adenocarcinoma model. Lentiviral vectors carried an 8-nt tag specific for an encoded guide RNA, as well as the 15-nt barcode for cancer cell quantification. In this experimental setup, in which different tumour suppressor genotypes were present within the same mouse, size and genotype of tumours were simultaneously determined by sequencing the guide RNA-specific barcode tag. Lkb1, Rb1, Cdkn2a and Apc were confirmed as tumour suppressors in Kras-driven lung cancer growth, and novel potential lung tumour suppressors (splicing factor Rbm10 and the methyltransferase Setd2) were found.

With its exceptional level of precision and reproducibility, Tuba-seq will be a powerful tool to determine the impact of loss-of-function mutations on tumour growth in vivo. Moreover, this approach can likely be adapted to other types of cancers and scaled up to even more extensively multiplexed libraries.


  1. 1

    Rogers, Z. N., McFarland, C. D., Winters, I. P. et al. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat. Met. (2017)

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trenkmann, M. Sizing up tumours with Tuba-seq. Nat Rev Genet 18, 456 (2017).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing